

# Capnography

## Application Note

This note provides you with a basic overview of the application and clinical benefits of capnography which is available on the entire IntelliVue patient monitor family. There is a choice between two state-of-art capnography solutions, enabling clinicians to select the method which best suits their use-model.

### Introduction

Capnography, which is also referred to as end tidal carbon dioxide (etCO<sub>2</sub>) monitoring, is a non-invasive measure of the inspired and expired carbon-dioxide concentration. It provides a graphical and numerical display of the partial pressure of carbon dioxide within the patients' airway. A detailed analysis of the waveform (capnogram) can reveal to the clinician both complex and subtle changes of the patients ventilatory status.

### Clinical Application

New technologies for monitoring etCO<sub>2</sub> now provide clinicians with the opportunity to easily monitor the ventilatory status in both spontaneously & mechanically assisted breathing patients. Several accessories have been designed to meet the most challenging applications. Together, they provide healthcare institutes with the tools that assist them to comply with the latest recommendations.

### Confirmation tracheal versus esophageal intubation

In some patient populations, it is difficult to directly visualize the vocal cords during intubation, therefore it is essential to confirm correct placement of the tube. Carbon dioxide is eliminated by the lungs, so the measure of etCO<sub>2</sub> and display of a capnogram confirms to the clinician the success of the procedure. If the tube is misplaced in the esophagus, then neither the etCO<sub>2</sub> value nor a normal capnogram will be displayed.

The American Heart Association guidelines for Advanced Cardiovascular Life Support recommend that emergency responders confirm tracheal tube positioning by using nonphysical examination techniques. These include

esophageal detector devices, quantitative end-tidal CO<sub>2</sub> indicators, and capnographic and capnometric devices, this includes capnography.

Continuous etCO<sub>2</sub> monitoring is extremely useful during patient repositioning when there is the risk of accidental tube displacement or extubation. The clinician is quickly alerted to this as the measured etCO<sub>2</sub> value will drop and the capnogram will lose its normal rectangular appearance.

### Monitoring severity of lung disease and impact of treatment

Since etCO<sub>2</sub> offers a measure of the alveolar O<sub>2</sub>/CO<sub>2</sub> exchange capabilities, clinicians are able to assess the effect of medications being used to treat asthma and chronic obstructive pulmonary disease in both intubated and non-intubated patients. As the therapy is given, the capnogram appearance is assessed for its slope and timing. The aim of therapy would be to have a near to normal capnogram displayed.

### Monitoring efficiency of mechanical ventilatory support

Patients who are intubated and receiving mechanical ventilatory support benefit from etCO<sub>2</sub> monitoring in several ways;

- Disappearance of the etCO<sub>2</sub> value & capnogram is suggested of ventilator disconnect. This may be detected on the patient monitor prior to the ventilator associated alarm.
- Rebreathing of CO<sub>2</sub> can be assessed by observing the upward trend of the capnogram over time.
- There is a correlation between the etCO<sub>2</sub> and PaCO<sub>2</sub>; a gradient between 1-5mmHg is normal & expected. When detecting a drop in etCO<sub>2</sub>, the clinician can measure the PaCO<sub>2</sub> and compare the two values. When there is a widened gradient, this is suggestive of a pulmonary emboli and the patient needs immediate investigation.
- One of the earliest indicators of insufficient neuromuscular blockade is the attempt of the patient to breath

spontaneously. This can be seen on the capnogram which will have a notched appearance.

### **Monitoring adequacy of pulmonary and coronary blood flow e.g. Cardiac Arrest**

Research has shown a close correlation between cardiac output and etCO<sub>2</sub> readings. Therefore several organizations are now recommending that during cardio-pulmonary resuscitation (CPR), etCO<sub>2</sub> be measured and used as an indicator effectiveness of CPR.

### **Monitoring spontaneous breathing in non-intubated patients receiving procedural sedation**

Pulse oximetry (SpO<sub>2</sub>) is the standard used for measuring oxygen saturation of the blood; however it does not provide an accurate snapshot of the patient's current ventilatory status. Studies have shown that the earliest indicator of respiratory depression and apnea are changes in the etCO<sub>2</sub> level, which occur long before changes are detected in the SpO<sub>2</sub> measurement.


Because SpO<sub>2</sub> does not provide information on the patients ventilatory status, the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and the American Society of Anesthetists (ASA) have revised their monitoring standards and now recommend that all patients under heavy sedation or anesthesia should have continuous monitoring of their respiratory measurements. The mandated use of capnography applies whenever drugs are administered that interfere with the protective airway reflex.

### **Helping Choose the Appropriate CO<sub>2</sub> Technology - Mainstream or Sidestream and/or Microstream®**

There are various types of CO<sub>2</sub> sampling technologies available with Philips. It is important to understand the difference between the applications in order to help you select the best option to satisfy your specific clinical requirements.

#### **Mainstream CO<sub>2</sub> Technology**

With mainstream CO<sub>2</sub> technologies, the CO<sub>2</sub> sensor is placed on an airway adapter which is directly in the breathing circuit. As a patient breathes or is ventilated, the sensor analyzes the gas passing through the adapter and reports the CO<sub>2</sub> values.



Mainstream technology is the ideal choice for intubated patients such as in the ICU. The benefits of this type of technology are that the measurement is made immediately at


the airway. There is no sample removed from the breathing circuit.

### **What is the limitation of mainstream for non-intubated patients?**

Because mainstream technology requires the insertion of an airway adapter into a breathing circuit, there is no easy connection for monitoring your non-intubated patients.

#### **Sidestream CO<sub>2</sub> and Microstream® Technology**

With sidestream and Microstream® technology, a nasal cannula is placed on the patient, or, if the patient is intubated, an airway adapter set is connected to the breathing circuit. As the patient breathes, a portion of the breath is transported through the sample line, filtered and analyzed by an infrared sensor.



Sidestream and Microstream® technology is the ideal choice for monitoring non-intubated patients such as in the ED for conscious sedation or for use as a safety monitor in the ICU after a patient has been extubated to help assure that the patient maintains adequate ventilation on their own.

### **What is the limitation of sidestream for intubated patients?**

Patients who require intubation and long term ventilation typically will have thick secretions that are expelled through coughing or by suctioning. Because sidestream technology requires that the gas sample be transported from the breathing circuit, through the sample line to reach the CO<sub>2</sub> analyzer, these secretions often will be aspirated into the sample line, causing the line to occlude requiring user intervention to correct the situation.

## Procedural Sedation case studies

Kindly provided by Oridion

Author; Jenifer R. Lightdale, MD, MPH. Children's Hospital Boston

### Case 1:

A 6 ½ year-old boy with gastroparesis and symptoms of gastroesophageal reflux presented for upper gastrointestinal endoscopy in a Pediatric Endoscopy Unit.

Baseline vital signs were found to be stable at 10:30 am, and revealed the patient to have an SpO<sub>2</sub> of 98% on room air. A dual-purpose nasal cannula was applied, and with 2L supplemental O<sub>2</sub> via nasal cannula, the patient's SpO<sub>2</sub> rose to 100%. A baseline ETCO<sub>2</sub> was noted to be 38 mm/Hg.

10 mg of midazolam po were administered at 10:50, and an IV was placed at 11:10am. At 12:00pm, the patient was brought to the procedure room, and sedation for the procedure was initiated at 12:10pm using a combination regimen of intravenous midazolam and fentanyl. Heart rate, respiratory rate, SpO<sub>2</sub>, blood pressure, chest impedance and capnography were all monitored throughout the procedure, and a dedicated nurse noted vital signs and chest wall movement continuously.

The endoscope was introduced into the patient's oropharynx at 12:22 and the esophagus was intubated and traversed without difficulty. At 12:24, the capnogram revealed 30 seconds of hypoalveolar ventilation and apnea. ETCO<sub>2</sub> detection at this time fell steadily from 35mmHg to undetectable.

Approximately 50 seconds later, at 12:25, the patient's pulse oximeter began to show arterial desaturation with a steady decline to a low of 84%. The patient was gently stimulated by the nursing staff, and the pulse oximetry reading had increased to 99% by 12:27.

Over the next 6 minutes, two further episodes of capnograms consistent with alveolar hypoventilation were noted, one lasting 25 seconds and the other lasting 50 seconds. No further arterial desaturation was noted on pulse oximetry, and the endoscope was withdrawn at 12:33.

The patient was discharged to the Post-Anesthesia Care Unit for recovery without complication.

### Case 2:

A 9 year-old boy with persistent gastroesophageal reflux presented for upper gastrointestinal endoscopy in a Pediatric Endoscopy Unit.

Baseline vital signs were found to be stable at 8:00 am, and revealed the patient to have an SpO<sub>2</sub> of 100% on room air. A dual-purpose nasal cannula was applied, and a baseline ETCO<sub>2</sub> was noted to be 37 mm/Hg.

The patient entered the procedure room, and sedation for the procedure was initiated at 8:35am using a combination regimen of intravenous midazolam and fentanyl. 2L of supplemental oxygen was provided via the nasal cannula.

Heart rate, respiratory rate, SpO<sub>2</sub>, blood pressure, chest impedance and capnography were all monitored throughout the procedure, and a dedicated nurse noted vital signs and chest wall movement continuously. At 8:47am, the patient was noted to be sleeping comfortably, with slow deep breaths, and his ETCO<sub>2</sub> was reading 48 mm/Hg.

The endoscope was introduced into the patient's oropharynx at 8:50 and the esophagus was intubated and traversed without difficulty. At 8:54, there was a 30 second episode of abnormal capnograms with occasional notching and loss of wave. At 9:04, there was a second episode lasting more than a minute of abnormal capnograms that included 25 seconds of frank loss of waveforms consistent with apnea. At 9:05, slightly more than 1 minute into this episode, the patient's pulse oximeter began to show arterial desaturation with a steady decline to a low of 89%. Meanwhile, the patient was being gently stimulated by the nursing staff. By 9:07am, the waveform had returned to a normal pattern, and the patient's pulse oximetry did not show desaturation. There were no further episodes of abnormal capnograms, and the procedure finished at 9:11am. The patient was discharged to the Post-Anesthesia Care Unit for recovery without complication.

**Philips Medical Systems is part of  
Royal Philips Electronics**

**Interested?**

Would you like to know more about our imaginative products? Please do not hesitate to contact us. We would be glad to hear from you.

*On the web*

**[www.medical.philips.com](http://www.medical.philips.com)**

*Via e-mail*

**[medical@philips.com](mailto:medical@philips.com)**

*By fax*

**+31 40 27 64 887**

*By postal service*

**Philips Medical Systems  
Global Information Center  
P.O Box 1168  
5602 BD Eindhoven  
The Netherlands**

*Asia*

Tel: +852 2821 5888

*Europe, Middle East, Africa*

Tel: +31 40 27 62092

*Latin America*

Tel: +55 11 2125 0764

*North America*

Tel: +1 800 285 5585

© Koninklijke Philips Electronics N.V. 2005

All rights are reserved. Reproduction in whole or in part is prohibited without the prior written consent of the copyright holder.

Philips Medical Systems Nederland B.V. reserves the right to make changes in specifications and/or to discontinue any product at any time without notice or obligation and will not be liable for any consequences resulting from the use of this publication.

Printed in The Netherlands.  
4522 962 16611 JUN 2006

**PHILIPS**